The patented product, developed by Venus Medicine Research Centre (VMRC) for the treatment of multidrug-resistant (MDR) infections, was sold to Cipla in 2019
Sun Pharma to set up Rs. 3,000 crore greenfield formulations facility in MP
Venus Remedies now has 29 active product approvals in Vietnam alone
Certification bolsters Venus Remedies' position in PIC/S markets, reinforcing commitment to global quality standards
This global affiliation marks a critical step in the company’s mission to create long-term value through ethical practices, scientific innovation, and inclusive healthcare delivery
The approval marks Venus Remedies’ strategic entry into complex generics, expanding its injectable portfolio beyond traditional formulations
MET-X, a novel metallo-beta-lactamase (MBL) inhibitor, has shown best-in-class performance in preclinical studies
Expects to unlock further opportunities in the Moldovan market, contributing anticipated sales of $300,000 in 2025 and approximately $700,000–$800,000 in 2026
Initiative aimed at enhancing workforce skills and competency in line with industry standards so as to create a talented workforce for the Fourth Industrial Revolution
Venus Remedies secures marketing authorization in Philippines
Subscribe To Our Newsletter & Stay Updated
